BPC-157 + KPV · gut-healing protocol
Community gut-healing stack. BPC-157 for mucosal repair + cytoprotection; KPV for downstream anti-inflammatory cytokine modulation. Common in IBD-symptom and post-antibiotic protocols.
Mechanism rationale
BPC-157 is gastric-derived and shows strong activity on gastrointestinal mucosa, which is the original isolation context. KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH and acts as an anti-inflammatory by modulating NF-kB pathways and pro-inflammatory cytokines (TNF-alpha, IL-6). The community rationale for combining them: BPC-157 rebuilds the mucosal barrier mechanically, KPV calms the inflammatory cascade that's driving the damage. Bangkok wellness clinics offer this combination as a gut-healing protocol; some IBD-symptom users run it alongside or in place of standard immunosuppressives.
Standard dose schedule
BPC-157 250 mcg sub-q daily (or split 125 mcg twice daily) + KPV 250 to 500 mcg sub-q daily, 4 to 8 week cycles. Some users take encapsulated KPV orally for local gut-luminal effect, accepting the bioavailability hit. Both compounds reconstituted in bacteriostatic water at 1 mg/mL. Note: this is community practice, not validated by formal trials.
Not medical advice. Reconstitution math at /tools/reconstitution-calculator.
The honest read
BPC-157 has reasonable animal data on gut mucosa + ulcer healing; human data is small. KPV has limited human data; the anti-inflammatory mechanism is published, magnitude of effect is modest, and most evidence is pre-clinical. The combination has zero formal trial data. Community reports are positive but heavily biased toward users who self-select for inflammatory bowel symptoms and stop reporting if they don't improve. Anyone considering this stack for diagnosed IBD should run it past their gastroenterologist; immunomodulation interactions with biologics or other immunosuppressives are real even at modest dose.
What both compounds share
Both compounds touch cell-proliferation or immune-modulation pathways. Active cancer is a hard contraindication for both. KPV's alpha-MSH-pathway connection raises a theoretical melanoma flag (though KPV does not engage MC1R directly); pre-existing melanocytic nevus surveillance is reasonable. Pregnancy + breastfeeding off-limits. Anyone on biologics, TNF inhibitors, or immunosuppressants needs specialist clearance.
Related Panya answers
If you have a specific tendon or joint injury that has plateaued on conservative management and you accept that the human evidence is thin, then yes, on a defined 4 to 6 week cycle...
BPC-157 if your injury is tendon, ligament, or gut. TB-500 if it's soft tissue (muscle tear, joint capsule). Stacking both is the community default but the human evidence does not ...
Standard community recovery stack: 250 mcg BPC-157 sub-q daily plus 2 mg TB-500 sub-q twice weekly for 4 to 6 weeks loading, then BPC-157 at 3 to 4 times weekly plus TB-500 once we...
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.
Last reviewed 2026-04-29. Stack pages refresh when literature, supply, or community practice shifts materially. Email partner@panya.health if you spot something we have wrong.